EMA's CHMP recommends new dosing schedule for Opdivo in melanoma
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy drug Opdivo (nivolumab) has secured recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for a new...
View ArticleBMS' Opdivo bests chemotherapy in oesophageal squamous cell carcinoma
Bristol-Myers Squibb took the opportunity at the European Society for Medical Oncology (ESMO) 2019 Annual Congress to present new Phase 3 data on its blockbuster immunotherapy Opdivo (nivolumab) in the...
View ArticleBMS' Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line...
Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo(nivolumab), showing that the drug, when combined with Yervoy (ipilimumab) and two cycles of...
View ArticleKeytruda overtakes Opdivo to lead sales in global immune checkpoint inhibitor...
MSD’s Keytruda (pembrolizumab) overtook Bristol-Myers Squibb’s (BMS) blockbuster drug Opdivo (nivolumab) in total sales in the third quarter of 2019 to emerge as leader in the global immune checkpoint...
View ArticleBMS pulls Opdivo+Yervoy combo in EU for advanced non-small cell lung cancer
Bristol-Myers Squibb has confirmed it has withdrawn its application with the European Commission for its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of advanced...
View ArticleOpdivo + cabiralizumab combo falls flat in advanced pancreatic cancer
Five Prime Therapeutics and Bristol-Myers Squibb have confirmed that their randomised Phase 2 trial investigating the efficacy of the former’s cabiralizumab combined with the latter’s blockbuster...
View ArticleBristol-Myers Squibb demonstrates potential for long-term survival in kidney...
Bristol-Myers Squibb has announced updated results from trialing Opdivo (nivolumab) plus Yervoy (ipilimumab) versus sunitinib in patients with previously untreated advanced or metastatic renal cell...
View ArticleOpdivo scores NICE recommendation in two non-small cell lung cancer indications
NICE has announced its recommendation of Bristol-Myers Squibb’s blockbuster immunotherapy drug Opdivo (nivolumab) for the treatment of two non-small cell lung cancer (NSCLC) indications in the...
View ArticleOpdivo/Yervoy combo secures FDA approval for malignant pleural mesothelioma
Bristol Myers Squibb’s therapy regimen of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) has secured FDA approval for the first-line treatment of unresectable malignant pleural...
View ArticleNICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery...
NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for the treatment of melanoma in patients post-surgery, it has been...
View Article
More Pages to Explore .....